Final

Question 1

NSCLC testing

Answer 1

EGFR Required

Gefitinib and Erlotinib

Question 2

Breast Cancer Testing

Answer 2

Her2 Required

Transtuzumab

Question 3

Abacavir Hypersensitivity

Answer 3

HLA-B*57:01 recommended

Caucasians at highest risk

Question 4

Carbamazepine Hypersensitivity

Answer 4

HLA-B*15:02 recomneded

asians at X10 risk (5%)

Question 5

Roche Amplichip Testing Instructions

Answer 5

for CYP2D6 and CYP2C19

blood sample > sample prep > amplification > Fragmentation/Labeling > Hybridization > analysis

Question 6

Invader

Answer 6

for UGT1A1 (ironotecan)
Sample prep > reagent prep > sample and regent to plate > incubation > analyze

Question 7

Immunosuppressive Drugs

Answer 7

Calcineurin inhibitors
Corticosteriods
antimetabolites
mTOR inhibitors
Antibody products

Question 8

Calcineurin inhibitors

Answer 8

cyclosporine

tacrolimus

Question 9

CYP3A4 polymorphism

Answer 9

*22 C>T

decrease dose

Question 10

CYP3A5 polymorphisms

Answer 10

• 3 A>G

* 6 G>A

Question 11

P-gp polymorphisms

Answer 11

C1236T
G2677T
C3435T
- C/T is IM
-WT is diff to ween off of steriods

Question 12

UGT Polymorphisms

Answer 12

Mycophenolate
1A8, 1A9, 2B7
UGT2b7 metabolized Mycophenolate to AcylMPAG

Question 13

TMPT polymorphisms

Answer 13

Azapthioprine > 6-MP > 6-MP (inactive)

*2 and *3

Question 14

AE in Transplantation

Answer 14

Nephrotoxicity
Neurotoxicity
HTN
Gi disturbances
NODAT

Question 15

NODAT info

Answer 15

9X higher than general pop
5-20% of people get NODAT
67.1% vs 81.9%

Question 16

NODAT Risk Factors

Answer 16

Clinical: Multiple CNI use, Obesity, Age, Rapamycin Use

Genetic Risk: SUR1, HNF1a, HNF4a, IRS, TCF7L2

Question 17

Colon Cancer Drugs

Answer 17

Cetuximab

Pantimumab

Question 18

Colon Cancer Mutations

Answer 18

KRAS and BRAF